MaxCyte, Inc. has entered into a technology license partnership with Genentech, a member of the Roche Group, to support the development of cell therapy programs. The agreement provides Genentech with access to MaxCyte’s ExPERT GTx platform and additional platform technologies across select research, clinical development, and manufacturing workflows. This partnership is structured to support multiple programs and enables Genentech to facilitate ex vivo applications for cell engineering.

The capabilities across MaxCyte platform technologies are designed to streamline the advancement of cell therapy programs by providing integrated access to support cell engineering from early discovery to cGMP manufacturing. The collaboration underscores MaxCyte’s expertise in enabling next-generation cell therapies by bringing together complementary technologies that support both cell engineering and analytical workflows across the development lifecycle.

Maher Masoud, President and CEO of MaxCyte, emphasized the strategic value of the partnership. "Cell therapy development increasingly requires technology partners that can support programs as they advance from research through development and manufacturing," said Masoud. "This partnership allows MaxCyte to provide broader support to Genentech across the cell therapy lifecycle by bringing together complementary capabilities in cell engineering and gene editing."

Partnership Details

The license agreement encompasses several key aspects of the collaboration:

• Platform Access: Genentech gains access to the ExPERT GTx platform and other MaxCyte technologies.
• Workflow Support: The partnership covers research, clinical development, and manufacturing stages.
• Scope: The agreement is structured to support multiple cell therapy programs.

About MaxCyte

MaxCyte is a cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. The company’s offerings include Flow Electroporation technology and SeQure gene editing characterization assessment services. For more than 25 years, MaxCyte has focused on advancing cell engineering to support the development of safe and effective treatments.

MaxCyte, Inc. will release its financial results for the second quarter of 2026 after the U.S. market close on Wednesday, August 12, 2026. Company management will host a conference call to discuss the financial results at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website.

Conference Call Details

MaxCyte is a cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics.